• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Galanin Receptor subtypes 2 as therapeutic targets in Head and Neck Squamous cell Carcinoma

Research Project

Project/Area Number 20592027
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Otorhinolaryngology
Research InstitutionJichi Medical University

Principal Investigator

KANAZAWA Takeharu  自治医科大学, 医学部, 准教授 (20336374)

Co-Investigator(Kenkyū-buntansha) ICHIMURA Keiichi  自治医科大学, 医学部, 教授 (00010471)
NISHINO Hiroshi  自治医科大学, 医学部, 准教授 (50245057)
Project Period (FY) 2008 – 2010
Project Status Completed (Fiscal Year 2010)
Budget Amount *help
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
KeywordsGALR2 / G蛋白共役受容体 / 癌抑制遺伝子 / 頭頸部癌 / G蛋白共役受 / GALR1 / G蛋白共役受容
Research Abstract

Purpose : Galanin and its receptors, GALR1 and GALR2, are known as tumor suppressor and focused as therapeutic targets in head and neck squamous cell carcinoma(HNSCC). Previously, we demonstrated that the function of signaling pathways of GALR1 and GALR2.In HNSCC cells with silenced GALR1 and GALR2, we showed that reexpressed GALR1 suppresseed tumor cell proliferation via the extracellular-regulated protein kinase-1/2(ERK1/2)-mediated effects on the cyclin-dependent kinase inhibitors(CKI) and cyclinD1.On the other hands, in the GALR2-transfected HNSCC cells, galanin suppressed proliferation and induced apoptosis. Galanin stimulation also mediated decreased expression of cyclin D1 and increased expression of the CKI, p27^<Kip1> and p57^<Kip2>. These effects were similar to GALR1, but GALR2 also induced caspase-3-dependent apoptosis, which was confirmed by Annexin-V staining and DNA fragmentation analysis. Thus, we understood the function of GALR1 and GALR2 as tumor suppressor, but the s … More ignaling pathway of GALR2 is still unclear. In this study, we investigated the signaling pathway of GALR2 in HNSCC cells that have mutant p53 and do not express GALR1.Experimental Design : The HNSCC cell line with a splice site mutation causing a 46-bp p53 off-frame deletion, was stably transfected to express GALR2 and examined the expression of phospho-ERK1/2 by immunoblotting. Results : Galanin treatment of the GALR2-transfected cells caused morphologic changes and a marked decrease in cell number that were not observed in the mock transfected cells. In the GALR2-transfected cells, galanin induced activation of the extracellular-regulated protein kinase-1/2(ERK1/2) and suppresses cell proliferation, not the mock. transected cells. Galanin stimulation also mediated decreased expression of cyclin D1.Pretreatment with the ERK1/2-specific inhibitor U0126 prevented the suppression of cyclin D1 expression. Conclusion : This study shows that reexpressed GALR2 also suppresses tumor cell proliferation via the almost same pathway for GALR1.However, the ERK1/2-specific inhibitor could not prevent the GALR2 mediated apoptosis. This study suggest that GALR2 uses the different signaling pathways to induce apoptosis or cell cycle arrest, but further investigations are need to understand the GALR2 signaling pathway in detail. Less

Report

(4 results)
  • 2010 Annual Research Report   Final Research Report ( PDF )
  • 2009 Annual Research Report
  • 2008 Annual Research Report
  • Research Products

    (6 results)

All 2011 2010 2009 2008

All Journal Article (4 results) (of which Peer Reviewed: 3 results) Presentation (2 results)

  • [Journal Article] Galanin receptor subtypes 1 and 2 as therapeutic targets in head and neck squamous cell carcinoma2010

    • Author(s)
      Kanazawa T, Misawa K, Carey TE
    • Journal Title

      Expert Opin Ther Targets

      Volume: 14 Pages: 289-302

    • Related Report
      2010 Final Research Report
  • [Journal Article] Galanin Receptor subtypes 1 and 2 as therapeutic targets in HNSCC2010

    • Author(s)
      Kanazawa, et al
    • Journal Title

      Expert Opinion of Therapeutic Target

      Volume: 14 Pages: 289-302

    • Related Report
      2010 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Galanin Receptor subtypes 1 and 2 as therapeutic targets in HNSCC2010

    • Author(s)
      Kanazawa, et al
    • Journal Title

      Expert Opinion of Therapeutic Target 14

      Pages: 289-302

    • Related Report
      2009 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Galanin Receptor subtype 2 suppresses cell proliferation and…2009

    • Author(s)
      Kanazawa, et al
    • Journal Title

      Clinical Cancer Research 15

      Pages: 2222-2230

    • Related Report
      2009 Annual Research Report
    • Peer Reviewed
  • [Presentation] GALR2 has the Different Signaling Pathway to Suppress Cell Proliferation and Induce Apoptosis in p53 Mutant Head and Neck Cancer Cells2011

    • Author(s)
      Kanazawa T, Carey TE
    • Organizer
      102^<th> Annual Meeting American Association for Cancer Research
    • Place of Presentation
      Orlando
    • Related Report
      2010 Annual Research Report 2010 Final Research Report
  • [Presentation] Galanin Receptor subtype 2 Suppresses Cell Proliferation and Induces Apoptosis in p53 Mutant Head and Neck Cancer Cells.2008

    • Author(s)
      Kanazawa T
    • Organizer
      7^<th> Internatinal Conference on Head and Neck Cancer
    • Place of Presentation
      San Francisco
    • Year and Date
      2008-07-19
    • Related Report
      2008 Annual Research Report

URL: 

Published: 2008-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi